Edaravone Attenuates Aβ 1-42-Induced Inflammatory Damage and Ferroptosis in HT22 Cells

Neurochem Res. 2023 Feb;48(2):570-578. doi: 10.1007/s11064-022-03782-y. Epub 2022 Nov 4.

Abstract

Ferroptosis and neuroinflammation play a crucial role in the pathogenesis of Alzheimer's disease (AD), and Edaravone (EDA) has been demonstrated to have anti-inflammatory, antioxidant and neuroprotective effects in neurodegenerative diseases. However, the relationship between EDA and ferroptosis in AD is unidentified. This research aimed to elucidate the mechanism of EDA in AD with Aβ 1-42-induced HT22 cells as in vitro cell model. The results showed that EDA could significantly reduce Aβ1-42-induced apoptosis of HT22 cells and formation of pro-inflammatory factors TNF-α, IL-1β and IL-6, prevent the activation of TLR4/NF-κB /NLRP3 signaling pathway, and inhibit ferroptosis and lipid peroxidation. Taken together, EDA contributes to inhibiting neuroinflammatory injury and ferroptosis in Aβ 1-42-induced HT22 cells, and thus may be a potential candidate for the treatment of AD.

Keywords: Aβ 1-42; Edaravone; Ferroptosis; HT22 cells; Neuroinflammation.

MeSH terms

  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / toxicity
  • Edaravone / pharmacology
  • Edaravone / therapeutic use
  • Ferroptosis*
  • Humans
  • NF-kappa B / metabolism
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Signal Transduction

Substances

  • Edaravone
  • Neuroprotective Agents
  • NF-kappa B
  • Amyloid beta-Peptides